This webinar will help you understand what is involved in an NDA including regulatory strategy, data integration and readiness, and electronic publishing, and provide tips that can help you avoid common pitfalls in the submissions process.
As the number of clinical trials increases so does the complexity and number of US and global sites needed to foster trial success. Read what was discovered after a survey on current site payment practices, how these practices are measured, what process improvement initiatives are currently being explored, what are some of the barriers to change, and what site payment trends will occur over the next five years. Download it now!
Take this quick 10 minute survey on on the state of sales enablement in the healthcare industry. A $5 Amazon Gift Card will be sent to the first 50 qualified respondents. Complete the survey now!
Hear new results from one of the industry's largest, global clinical operations surveys, the Veeva 2018 Unified Clinical Operations Survey. The Veeva 2018 Unified Clinical Operations Survey examines the industry’s progress toward a unified clinical operating environment.
Learn why unifying clinical applications is an industrywide priority for clinical operations leaders. Read the report.
Researchers are encumbered with a plethora of disparate data and analytic tools. These assets pose several challenges which need to be overcome to ensure they satisfy their intended purpose.
Join this webinar to learn how real-time, self-service access to longitudinal patient data is changing the way researchers evaluate treatment effectiveness, safety, protocol design, and more. Register now.
Fraud and fabrication is no laughing matter in the realm of clinical trials.
This webinar will outline the ways in which sponsors and CROs can remain diligent by being aware of signs of possible fraud and fabricated data throughout the course of the study.
A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today!
The first precision medicine CRO designed specifically for oncology and rare disease, Precision unifies translational science expertise and unparalleled clinical operations to create a more efficient process, deeper data, and an accelerated development pathway for novel treatments.
With 1200+ experts worldwide, one core team delivers
- Clinical development planning
- Expedited study start up enabled by Precision’s Oncology Site Network
- Personalized clinical trial execution services
- Specialty labs services and coordination
- Robust biometrics teams and services
This webinar will benefit Biotech executives interested in aligning their products for success via early strategy for 505(b)(2) drug development. Register Now
When it comes to choosing a partner, who do you want on your team? How about a provider with 52 patents, 17 candidates and work on 80% of the oncology therapies approved in 2017? Our next success can be yours. Choose Charles River to guide your therapy through the complex path to clinic with proven expertise and the industry’s most comprehensive portfolio. Learn More.
The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Read more.
In response to an increasing market demand, Cambrex has invested in a Continuous Flow Center enabling development of previously unfeasible process steps. Register for the Cambrex webinar on Continuous Flow Chemistry for APIs and Intermediates today.
FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs. Download the episode on iTunes or Stitcher, or listen here--and be sure to subscribe.
FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.
FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.
Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals. Click here to listen now.